Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay
Kinoshita, T., Sugiyama, H., Mori, Y., Takahashi, N., Tomonaga, A.(2016) Bioorg Med Chem Lett 26: 955-958
- PubMed: 26733474 
- DOI: 10.1016/j.bmcl.2015.12.056
- Primary Citation of Related Structures:  
5AX3 - PubMed Abstract: 
Extracellular signal-regulated kinase 2 (ERK2) is a drug target for type 2 diabetes mellitus. A peptide-type ERK2 inhibitor (PEP) was discovered in the previous study through the knowledge-based method and showed physiological effects on the db/db mice model of type 2 diabetes ...